GENINUS Inc.
GENINUS operates the IntelliMed, MEDINSIGHT, and SPACEINSIGHT data analytics platforms for precision medicine and drug development.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2018 and listed on KOSDAQ in 2021, GENINUS is a data analytics platform company supporting precision medicine and drug development. Its core businesses are IntelliMed, which integrates single-cell and spatial transcriptomic data to discover novel drug targets, MEDINSIGHT, an AI-based digital pathology platform automating pathology image analysis, and SPACEINSIGHT, which integrates spatial omics and pathology imaging analysis. The company obtained GCLP certification in October 2024 and CAP certification in December 2020 (valid through December 2026), with global and domestic large pharmaceutical companies developing anticancer, ADC, and immuno-oncology drugs as key customers.
Products & technology
- IntelliMedPlatform integrating single-cell transcriptomic, spatial transcriptomic, and spatial proteomic data to discover novel drug targets and combinations
- MEDINSIGHTAI-based digital pathology platform automating cell type annotation, tumor microenvironment quantification, and biomarker expression analysis from H&E and IHC pathology images
- SPACEINSIGHTPlatform integrating spatial transcriptomic, spatial proteomic, and pathology image data to assess tumor microenvironment structure, cell-cell interactions, and spatial target uniformity
Regulatory approvals
data.go.kr4 Korean MFDS device approvals · 2022–2026
- MFDSIVD reagents for cancer related gene2026-01-08Product approval · Class 3체외 제허 26-20 호
- MFDSIVD reagents for cancer related gene2025-11-27Product approval · Class 3체외 제허 25-801 호
- MFDSIVD reagents for cancer related gene2025-11-27Product approval · Class 3체외 제허 25-800 호
- MFDSIVD reagents for cancer related geneRevoked2022-10-04Product approval · Class 3체외 제허 22-661 호
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.
Cancer molecular diagnostics company behind the EarlyTect-C stool-based colorectal cancer test using the SDC2 methylation biomarker.
Founded in 1976 and KOSDAQ-listed in 2000, HLB PANAGENE develops PNA-based molecular diagnostic and diagnostic automation products.
KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.
KOSDAQ-listed precision-diagnostics company manufacturing genomic diagnostic reagents and developing related software.
Optipharm, founded in 2000 and KOSDAQ-listed in 2018, provides animal disease diagnostics, animal medicine, and biotech.
Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition